



January 17, 2019

To Whom It May Concern

Company : Fuji Pharma Co., Ltd.
Representative : President and Representative Director Eiji Takemasa
(Code: 4554, Tokyo Stock Exchange, First Section)
Director and Managing Executive Officer
Inquiries : General Manager, Corporate Planning Division
Toyoyuki Kamide
TEL : 03-3556-3344

Notice on completion of Investment in Alvotech Holding

Based on the investment agreement concluded on December 16, 2018, the Company has completed the payment of investment in Alvotech Holding (Head Office: Luxembourg).

1. Outline of investment

(1) Number of shares to be acquired	281,400 shares (number of voting rights: 281,400)
(2) Acquisition price	USD 49,999,152
(3) Number of shares held after transfer	281,400 shares (number of voting rights: 281,400) (proportion of voting rights held: 4.22%)

End